Associations of FGF21 and GDF15 with mitochondrial dysfunction in children living with perinatally-acquired HIV: A cross-sectional evaluation of pediatric AIDS clinical trials group 219/219C
Open Access
- 31 December 2021
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 16 (12) , e0261563
Abstract
Background: In persons living with HIV, mitochondrial disease (MD) is difficult to diagnose, as clinical signs are non-specific with inconsistent patterns. Fibroblast growth factor 21 (FGF21) and growth differentiation factor 15 (GDF15) are mitokines elevated in MD patients without HIV, and associated with cardiometabolic comorbidities in adults living with HIV. We assessed relationships of these biomarkers with MD in children living with perinatally-acquired HIV infection (CPHIV). Setting: Cross-sectional study of CPHIV from Pediatric ACTG 219/219C classified by Mitochondrial Disease Criteria (MDC) that defines scores 2–4 as “possible” MD. Methods: Each case with MDC equaling 4 (MDC4; n = 23) was matched to one randomly selected control displaying no MDC (MDC0; n = 23) based on calendar date. Unmatched cases with MDC equaling 3 (MDC3; n = 71) were also assessed. Plasma samples proximal to diagnoses were assayed by ELISA. Mitokine distributions were compared using Wilcoxon tests, Spearman correlations were calculated, and associations with MD status were assessed by conditional logistic regression. Results: Median FGF21 and GDF15 concentrations, respectively, were highest in MDC4 (143.9 and 1441.1 pg/mL), then MDC3 (104.0 and 726.5 pg/mL), and lowest in controls (89.4 and 484.7 pg/mL). Distributions of FGF21 (paired Wilcoxon rank sum p = 0.002) and GDF15 (paired Wilcoxon rank sum p<0.001) differed in MDC4 vs MDC0. Mitokine concentrations were correlated across all participants (r = 0.33; p<0.001). Unadjusted odds ratios of being MDC4 vs MDC0 were 5.2 [95% confidence interval (CI): 1.06–25.92] for FGF21 and 3.5 (95%CI: 1.19–10.25) for GDF15. Relationships persisted after covariate adjustments. Conclusion: FGF21 and GDF15 levels may be useful biomarkers to screen for CPHIV with mitochondrial dysfunction.Keywords
Funding Information
- National Institutes of Health (P20GM113134)
- University of Hawaii (U54MD007584)
This publication has 32 references indexed in Scilit:
- Growth differentiation factor-15 in young sickle cell disease patients: Relation to hemolysis, iron overload and vascular complicationsBlood Cells, Molecules, and Diseases, 2014
- Effects of lifestyle modification and metformin on irisin and FGF21 among HIV‐infected subjects with the metabolic syndromeClinical Endocrinology, 2014
- Significant gender difference in serum levels of fibroblast growth factor 21 in Danish children and adolescentsInternational Journal of Pediatric Endocrinology, 2014
- Short Communication: The Relationship Between Mitochondrial Dysfunction and Insulin Resistance in HIV-Infected Children Receiving Antiretroviral TherapyAIDS Research and Human Retroviruses, 2013
- Elevated serum fibroblast growth factor 21 levels correlate with immune recovery but not mitochondrial dysfunction in HIV infectionAIDS Research and Therapy, 2013
- Metabolic abnormalities and viral replication are associated with biomarkers of vascular dysfunction in HIV‐infected childrenHIV Medicine, 2011
- FGF-21 as a biomarker for muscle-manifesting mitochondrial respiratory chain deficiencies: a diagnostic studyThe Lancet Neurology, 2011
- Serum FGF21 in boys with idiopathic short stature: relationship to lipid profile, onset of puberty and growth*Clinical Endocrinology, 2011
- Possible Mitochondrial Dysfunction and Its Association with Antiretroviral Therapy Use in Children Perinatally Infected with HIVThe Journal of Infectious Diseases, 2010
- Relationship between HIV/Highly Active Antiretroviral Therapy (HAART)–Associated Lipodystrophy Syndrome and Stavudine‐Triphosphate Intracellular Levels in Patients with Stavudine‐Based Antiretroviral RegimensClinical Infectious Diseases, 2010